{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:53:40Z","timestamp":1777521220723,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To provide real-world experiences of treating polypoidal choroidal vasculopathy (PCV) patients with photodynamic therapy (PDT) plus intravitreal injection of ranibizumab or intravitreal injection of aflibercept alone. Retrospective chart review of patients with PCV in a single tertiary referral center in Taiwan. Chart review of PCV patients treated with PDT and injection of ranibizumab or injection of aflibercept. A total of 101 eyes of 101 patients (38 females and 63 males) were reviewed. Of those, 48 and 53 eyes received primary\/adjunctive PDT along with injections of ranibizumab or intravitreal injections of aflibercept only, respectively. Initial visual acuity (VA) and central subfield choroidal thickness were similar between the two groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In addition, changes in VA at 3, 6, and 12\u00a0months post treatment were similar. The central retinal thickness decreased with either treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01); however, this change did not translate into VA performance (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In the subgroup analysis of pachychoroid and non-pachychoroid patients, better initial VA and post-treatment VA at 3\u00a0months and 6\u00a0months was noted in the latter group of patients treated with anti-vascular endothelial growth factor monotherapy (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). Aflibercept monotherapy is comparable with PDT plus ranibizumab in PCV patients with PCV (pachychoroid and non-pachychoroid patients). In addition, better prognosis regarding VA was observed in non-pachychoroid patients treated with aflibercept monotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-99634-w","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T10:18:43Z","timestamp":1633947523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"11","author":[{"given":"I-Hsin","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzyy-Chang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tso-Ting","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-May","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"issue":"1","key":"99634_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi, L. A., Sorenson, J., Spaide, R. F. & Lipson, B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10(1), 1\u20138 (1990).","journal-title":"Retina"},{"key":"99634_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong, C. W. et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog. Retin. Eye Res. 53, 107\u2013139 (2016).","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"99634_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung, C. M. G. et al. Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management. Ophthalmology 125(5), 708\u2013724 (2018).","journal-title":"Ophthalmology"},{"issue":"1","key":"99634_CR4","doi-asserted-by":"publisher","first-page":"9701","DOI":"10.1038\/s41598-019-46235-3","volume":"9","author":"K Bae","year":"2019","unstructured":"Bae, K., Noh, S. R., Kang, S. W., Kim, E. S. & Yu, S. Y. Angiographic subtypes of neovascular age-related macular degeneration in Korean: A new diagnostic challenge. Sci. Rep. 9(1), 9701 (2019).","journal-title":"Sci. Rep."},{"issue":"8","key":"99634_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/archopht.117.8.1035","volume":"117","author":"M Uyama","year":"1999","unstructured":"Uyama, M. et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch. Ophthalmol. 117(8), 1035\u20131042 (1999).","journal-title":"Arch. Ophthalmol."},{"issue":"8","key":"99634_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/bjo.86.8.892","volume":"86","author":"AK Kwok","year":"2002","unstructured":"Kwok, A. K., Lai, T. Y., Chan, C. W., Neoh, E. L. & Lam, D. S. Polypoidal choroidal vasculopathy in Chinese patients. Br. J. Ophthalmol. 86(8), 892\u2013897 (2002).","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"99634_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12886-019-1245-4","volume":"19","author":"J Yang","year":"2019","unstructured":"Yang, J., Yuan, M., Wang, E., Xia, S. & Chen, Y. Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: A retrospective study. BMC Ophthalmol. 19(1), 237 (2019).","journal-title":"BMC Ophthalmol."},{"issue":"1","key":"99634_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/jop.2009.0073","volume":"26","author":"TY Lai","year":"2010","unstructured":"Lai, T. Y. et al. Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. J. Ocul. Pharmacol. Ther. 26(1), 91\u201395 (2010).","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"3","key":"99634_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/bjo.2008.150029","volume":"94","author":"GT Kokame","year":"2010","unstructured":"Kokame, G. T., Yeung, L. & Lai, J. C. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br. J. Ophthalmol. 94(3), 297\u2013301 (2010).","journal-title":"Br. J. Ophthalmol."},{"issue":"11","key":"99634_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh, A. et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial. JAMA Ophthalmol. 135(11), 1206\u20131213 (2017).","journal-title":"JAMA Ophthalmol."},{"issue":"11","key":"99634_CR11","first-page":"1802","volume":"11","author":"SN Chen","year":"2018","unstructured":"Chen, S. N. et al. One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: A subgroup analysis of the REAL study. Int. J. Ophthalmol. 11(11), 1802\u20131808 (2018).","journal-title":"Int. J. Ophthalmol."},{"issue":"5","key":"99634_CR12","first-page":"1056","volume":"8","author":"K Tang","year":"2015","unstructured":"Tang, K. et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: A systematic review and Meta-analysis. Int. J. Ophthalmol. 8(5), 1056\u20131066 (2015).","journal-title":"Int. J. Ophthalmol."},{"issue":"5","key":"99634_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","volume":"31","author":"CK Cheng","year":"2011","unstructured":"Cheng, C. K., Peng, C. H., Chang, C. K., Hu, C. C. & Chen, L. J. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy. Retina 31(5), 846\u2013856 (2011).","journal-title":"Retina"},{"issue":"8","key":"99634_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","volume":"31","author":"TY Lai","year":"2011","unstructured":"Lai, T. Y., Lee, G. K., Luk, F. O. & Lam, D. S. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 31(8), 1581\u20131588 (2011).","journal-title":"Retina"},{"issue":"9","key":"99634_CR15","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","volume":"122","author":"A Yamamoto","year":"2015","unstructured":"Yamamoto, A. et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 122(9), 1866\u20131872 (2015).","journal-title":"Ophthalmology"},{"issue":"8","key":"99634_CR16","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh, A. et al. EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8), 1453\u20131464 (2012).","journal-title":"Retina"},{"issue":"1","key":"99634_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajo.2010.02.008","volume":"150","author":"F Gomi","year":"2010","unstructured":"Gomi, F. et al. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am. J. Ophthalmol. 150(1), 48-54.e41 (2010).","journal-title":"Am. J. Ophthalmol."},{"issue":"8","key":"99634_CR18","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi, F. et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan study. Retina 35(8), 1569\u20131576 (2015).","journal-title":"Retina"},{"issue":"1","key":"99634_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajo.2011.07.001","volume":"153","author":"K Tomita","year":"2012","unstructured":"Tomita, K. et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am. J. Ophthalmol. 153(1), 68-80.e61 (2012).","journal-title":"Am. J. Ophthalmol."},{"issue":"9","key":"99634_CR20","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00417-013-2323-6","volume":"251","author":"M Saito","year":"2013","unstructured":"Saito, M., Iida, T., Kano, M. & Itagaki, K. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 251(9), 2099\u20132110 (2013).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"99634_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41598-020-80731-1","volume":"11","author":"L Yeung","year":"2021","unstructured":"Yeung, L. et al. Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: A real-world study. Sci. Rep. 11(1), 470 (2021).","journal-title":"Sci. Rep."},{"key":"99634_CR22","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/OPTH.S171015","volume":"12","author":"K Takahashi","year":"2018","unstructured":"Takahashi, K. et al. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clin. Ophthalmol. 12, 1789\u20131799 (2018).","journal-title":"Clin. Ophthalmol."},{"issue":"7","key":"99634_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee, W. K. et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial. JAMA Ophthalmol. 136(7), 786\u2013793 (2018).","journal-title":"JAMA Ophthalmol."},{"issue":"2","key":"99634_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jfma.2019.04.012","volume":"119","author":"LJ Chen","year":"2019","unstructured":"Chen, L. J., Cheng, C. K., Yeung, L., Yang, C. H. & Chen, S. J. Management of polypoidal choroidal vasculopathy: Experts consensus in Taiwan. J. Formos. Med. Assoc. 119(2), 569\u2013576 (2019).","journal-title":"J. Formos. Med. Assoc."},{"issue":"7","key":"99634_CR25","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1167\/iovs.12-9619","volume":"53","author":"P Jirarattanasopa","year":"2012","unstructured":"Jirarattanasopa, P. et al. Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy. Investig. Ophthalmol. Vis. Sci. 53(7), 3663\u20133672 (2012).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"8","key":"99634_CR26","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim, H. et al. Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 254(8), 1497\u20131503 (2016).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"99634_CR27","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1038\/s41598-020-65346-w","volume":"10","author":"K Azuma","year":"2020","unstructured":"Azuma, K. et al. Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy. Sci. Rep. 10(1), 8337 (2020).","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"99634_CR28","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1097\/IAE.0000000000001346","volume":"36","author":"WK Lee","year":"2016","unstructured":"Lee, W. K., Baek, J., Dansingani, K. K., Lee, J. H. & Freund, K. B. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina 36(Suppl 1), S73\u2013S82 (2016).","journal-title":"Retina"},{"issue":"1","key":"99634_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41433-018-0158-4","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung, C. M. G. et al. Pachychoroid disease. Eye (Lond). 33(1), 14\u201333 (2019).","journal-title":"Eye (Lond)."},{"issue":"7","key":"99634_CR30","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","volume":"40","author":"YC Chang","year":"2019","unstructured":"Chang, Y. C. & Cheng, C. K. Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina 40(7), 1403\u20131411 (2019).","journal-title":"Retina"},{"key":"99634_CR31","doi-asserted-by":"crossref","unstructured":"Yoneda A, Wakiyama H, Kurihara J, Kitaoka T. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy. Eur J Ophthalmol. 2019:1120672119871886.","DOI":"10.1177\/1120672119871886"},{"issue":"1","key":"99634_CR32","doi-asserted-by":"publisher","first-page":"e12840","DOI":"10.1111\/eci.12840","volume":"48","author":"T Qian","year":"2018","unstructured":"Qian, T., Li, X., Zhao, M. & Xu, X. Polypoidal choroidal vasculopathy treatment options: A meta-analysis. Eur. J. Clin. Investig. 48(1), e12840 (2018).","journal-title":"Eur. J. Clin. Investig."},{"issue":"3","key":"99634_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00417-016-3468-x","volume":"255","author":"K Takayama","year":"2017","unstructured":"Takayama, K. et al. Short-term focal macular electroretinogram of eyes treated by aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 255(3), 449\u2013455 (2017).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"5","key":"99634_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2018-311963","volume":"103","author":"M Miyata","year":"2018","unstructured":"Miyata, M. et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. Br. J. Ophthalmol. 103(5), 617\u2013622 (2018).","journal-title":"Br. J. Ophthalmol."},{"issue":"9","key":"99634_CR35","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/eye.2015.101","volume":"29","author":"CS Tan","year":"2015","unstructured":"Tan, C. S., Ngo, W. K., Lim, L. W. & Lim, T. H. Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab. Eye (Lond). 29(9), 1238 (2015).","journal-title":"Eye (Lond)."},{"key":"99634_CR36","doi-asserted-by":"publisher","first-page":"1609717","DOI":"10.1155\/2019\/1609717","volume":"2019","author":"J Yang","year":"2019","unstructured":"Yang, J., Yuan, M., Xia, S. & Chen, Y. Six-year real-world outcomes of antivascular endothelial growth factor monotherapy and combination therapy for various subtypes of polypoidal choroidal vasculopathy. J. Ophthalmol. 2019, 1609717 (2019).","journal-title":"J. Ophthalmol."},{"issue":"6","key":"99634_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00417-020-04620-z","volume":"258","author":"K Lee","year":"2020","unstructured":"Lee, K., Park, J. H., Park, Y. G. & Park, Y. H. Analysis of choroidal thickness and vascularity in patients with unilateral polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 258(6), 1157\u20131164 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"8","key":"99634_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi, Y. et al. Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina 38(8), 1509\u20131517 (2018).","journal-title":"Retina"},{"issue":"12","key":"99634_CR39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","volume":"3","author":"M Hata","year":"2019","unstructured":"Hata, M. et al. Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol. Retina 3(12), 1016\u20131025 (2019).","journal-title":"Ophthalmol. Retina"},{"issue":"9","key":"99634_CR40","doi-asserted-by":"publisher","first-page":"e0184058","DOI":"10.1371\/journal.pone.0184058","volume":"12","author":"M Kong","year":"2017","unstructured":"Kong, M., Kim, S. M. & Ham, D. I. Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy. PLoS ONE 12(9), e0184058 (2017).","journal-title":"PLoS ONE"},{"issue":"8","key":"99634_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","volume":"249","author":"H Koizumi","year":"2011","unstructured":"Koizumi, H., Yamagishi, T., Yamazaki, T., Kawasaki, R. & Kinoshita, S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 249(8), 1123\u20131128 (2011).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"9","key":"99634_CR42","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00417-010-1365-2","volume":"248","author":"R Mori","year":"2010","unstructured":"Mori, R., Yuzawa, M., Lee, Z., Haruyama, M. & Akaza, E. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol. 248(9), 1233\u20131239 (2010).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"5","key":"99634_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ajo.2012.03.051","volume":"154","author":"YA Lee","year":"2012","unstructured":"Lee, Y. A. et al. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: Two years of follow-up. Am. J. Ophthalmol. 154(5), 872-880.e872 (2012).","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"99634_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41598-018-36704-6","volume":"9","author":"TT Lai","year":"2019","unstructured":"Lai, T. T., Hsieh, Y. T., Yang, C. M., Ho, T. C. & Yang, C. H. Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: A real-world study. Sci. Rep. 9(1), 529 (2019).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99634-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99634-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T05:09:59Z","timestamp":1675746599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99634-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99634"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99634-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20115"}}